New Phase 3 results for rinatabart sesutecan (Rina-S), the lead antibody-drug conjugate acquired through Genmab’s $1.8B purchase of Seattle-based ProfoundBio in 2024, demonstrated significant improvements in progression-free and overall survival for patients with platinum-resistant ovarian cancer.
Genmab Reports Positive Phase 3 Data for Rina-S, Acquired Through Seattle’s ProfoundBio
Share: